首页 > 最新文献

Canada communicable disease report = Releve des maladies transmissibles au Canada最新文献

英文 中文
Utility of the Peterborough Public Health COVID-19 rapid antigen test self-report tool: Implications for COVID-19 surveillance. 彼得伯勒公共卫生 COVID-19 快速抗原检测自我报告工具的实用性:对 COVID-19 监测的影响。
Erin Smith, Carolyn Pigeau, Jamal Ahmadian-Yazdi, Mohamed Kharbouch, Jane Hoffmeyer, Thomas Piggott

Background: The ongoing coronavirus disease 2019 (COVID-19) pandemic has necessitated novel testing strategies, including the use of rapid antigen tests (RATs). The widespread distribution of RATs to the public prompted Peterborough Public Health to launch a pilot RAT self-report tool to assess its utility in COVID-19 surveillance. The objective of this study is to investigate the utility of RAT using correlations between RAT self-report results and other indicators of COVID-19.

Methods: We investigated the association between RAT results, PCR test results and wastewater levels of nmN1N2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genes (to infer COVID-19 levels) using Pearson's correlation coefficient. Percent positivity and count of positive tests for RATs and polymerase chain reaction (PCR) tests were analyzed.

Results: The PCR percent positivity and wastewater were weakly correlated (r=0.33, p=0.022), as were RAT percent positivity and wastewater nmN1N2 levels (r=0.33, p=0.002). The RAT percent positivity and PCR percent positivity were not significantly correlated (r=-0.035, p=0.75). Count of positive RATs and count of positive PCR tests were moderately correlated (r=0.59, p<0.001). Wastewater nmN1N2 levels were not significantly correlated with either count of positive RATs (r=0.019, p=0.864) or count of positive PCR tests (r=0.004, p=0.971).

Conclusion: Our results support the use of RAT self-reporting as a low-cost simple adjunctive COVID-19 surveillance tool, and suggest that its utility is greatest when considering an absolute count of positive RATs rather than percent positivity due to reporting bias towards positive tests. These results can help inform COVID-19 surveillance strategies of local public health units and encourage the use of a RAT self-report tool.

背景:由于冠状病毒病 2019(COVID-19)大流行,有必要采用新的检测策略,包括使用快速抗原检测(RAT)。快速抗原检测仪在公众中的广泛使用促使彼得伯勒公共卫生部门启动了一项快速抗原检测仪自我报告工具试点,以评估其在 COVID-19 监测中的实用性。本研究的目的是利用 RAT 自我报告结果与 COVID-19 的其他指标之间的相关性来调查 RAT 的实用性:我们使用皮尔逊相关系数调查了 RAT 结果、PCR 检测结果和 nmN1N2 严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)基因废水水平(推断 COVID-19 水平)之间的关联。对 RAT 和聚合酶链反应(PCR)检测的阳性百分比和阳性计数进行了分析:PCR阳性率与废水呈弱相关(r=0.33,p=0.022),RAT阳性率与废水中 nmN1N2 水平也呈弱相关(r=0.33,p=0.002)。RAT 阳性率与 PCR 阳性率无显著相关性(r=-0.035,p=0.75)。RAT 阳性计数和 PCR 阳性计数呈中度相关(r=0.59,pp=0.864)或 PCR 阳性计数呈中度相关(r=0.004,p=0.971):我们的研究结果支持将 RAT 自我报告作为一种低成本、简单的 COVID-19 辅助监测工具,并表明由于阳性检测的报告偏差,在考虑阳性 RAT 的绝对数量而非阳性百分比时,其效用最大。这些结果有助于为地方公共卫生单位的 COVID-19 监测策略提供信息,并鼓励使用 RAT 自我报告工具。
{"title":"Utility of the Peterborough Public Health COVID-19 rapid antigen test self-report tool: Implications for COVID-19 surveillance.","authors":"Erin Smith, Carolyn Pigeau, Jamal Ahmadian-Yazdi, Mohamed Kharbouch, Jane Hoffmeyer, Thomas Piggott","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The ongoing coronavirus disease 2019 (COVID-19) pandemic has necessitated novel testing strategies, including the use of rapid antigen tests (RATs). The widespread distribution of RATs to the public prompted Peterborough Public Health to launch a pilot RAT self-report tool to assess its utility in COVID-19 surveillance. The objective of this study is to investigate the utility of RAT using correlations between RAT self-report results and other indicators of COVID-19.</p><p><strong>Methods: </strong>We investigated the association between RAT results, PCR test results and wastewater levels of nmN1N2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genes (to infer COVID-19 levels) using Pearson's correlation coefficient. Percent positivity and count of positive tests for RATs and polymerase chain reaction (PCR) tests were analyzed.</p><p><strong>Results: </strong>The PCR percent positivity and wastewater were weakly correlated (r=0.33, <i>p</i>=0.022), as were RAT percent positivity and wastewater nmN1N2 levels (r=0.33, <i>p</i>=0.002). The RAT percent positivity and PCR percent positivity were not significantly correlated (r=-0.035, <i>p</i>=0.75). Count of positive RATs and count of positive PCR tests were moderately correlated (r=0.59, <i>p</i><0.001). Wastewater nmN1N2 levels were not significantly correlated with either count of positive RATs (r=0.019, <i>p=</i>0.864) or count of positive PCR tests (r=0.004, <i>p</i>=0.971).</p><p><strong>Conclusion: </strong>Our results support the use of RAT self-reporting as a low-cost simple adjunctive COVID-19 surveillance tool, and suggest that its utility is greatest when considering an absolute count of positive RATs rather than percent positivity due to reporting bias towards positive tests. These results can help inform COVID-19 surveillance strategies of local public health units and encourage the use of a RAT self-report tool.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 2-3","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Event-based surveillance: Providing early warning for communicable disease threats. 基于事件的监控:为传染病威胁提供预警。
Tenzin Norzin, Homeira Ghiasbeglou, Marcia Patricio, Svetlana Romanova, Abdelhamid Zaghlool, Florence Tanguay, Linlu Zhao

The coronavirus disease 2019 pandemic served as a compelling modern-day reminder of the value of early warning against communicable disease threats in public health. As countries exit the acute phase of the pandemic, there remains a continued need to be vigilant for potential communicable disease threats, particularly as the risk of animal-to-human spillover events is increasing due to climate and land use change. Early warning of emerging threats facilitates earlier public health response, which affords more time to implement public health measures that can help minimize the impact of a particular health threat and protect the health and well-being of the population. One approach to providing early warning for communicable disease and other threats is through event-based surveillance (EBS). However, EBS is not often discussed in the context of public health surveillance. This overview introduces EBS and how it might contribute to providing early warning for communicable disease threats.

2019 年冠状病毒疾病大流行是现代公共卫生领域对传染病威胁预警价值的一次有力提醒。随着各国走出大流行病的急性期,仍然需要继续警惕潜在的传染病威胁,特别是由于气候和土地使用的变化,动物传染给人类的风险正在增加。对新出现的威胁发出预警有助于更早地作出公共卫生反应,从而有更多的时间来实施公共卫生措施,以帮助最大限度地减少特定健康威胁的影响,保护人民的健康和福祉。提供传染病和其他威胁预警的一种方法是基于事件的监测(EBS)。然而,在公共卫生监测的背景下,人们并不经常讨论 EBS。本概述将介绍 EBS 及其如何有助于提供传染病威胁预警。
{"title":"Event-based surveillance: Providing early warning for communicable disease threats.","authors":"Tenzin Norzin, Homeira Ghiasbeglou, Marcia Patricio, Svetlana Romanova, Abdelhamid Zaghlool, Florence Tanguay, Linlu Zhao","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The coronavirus disease 2019 pandemic served as a compelling modern-day reminder of the value of early warning against communicable disease threats in public health. As countries exit the acute phase of the pandemic, there remains a continued need to be vigilant for potential communicable disease threats, particularly as the risk of animal-to-human spillover events is increasing due to climate and land use change. Early warning of emerging threats facilitates earlier public health response, which affords more time to implement public health measures that can help minimize the impact of a particular health threat and protect the health and well-being of the population. One approach to providing early warning for communicable disease and other threats is through event-based surveillance (EBS). However, EBS is not often discussed in the context of public health surveillance. This overview introduces EBS and how it might contribute to providing early warning for communicable disease threats.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 1","pages":"29-34"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10712973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality over quantity in active tick surveillance: Sentinel surveillance outperforms risk-based surveillance for tracking tick-borne disease emergence in southern Canada. 蜱虫主动监测的质量重于数量:在跟踪加拿大南部出现的蜱传疾病方面,哨点监测优于基于风险的监测。
Camille Guillot, Catherine Bouchard, Kayla Buhler, Roxane Pelletier, François Milord, Patrick Leighton

Background: Lyme disease (LD) emerged in southern Québec at the start of the century, with many municipalities now endemic. A coordinated active surveillance programme has been in place in the province of Québec since 2014, including a limited number of sentinel field sites resampled each year and a larger set of accessory field sites that change yearly according to the LD surveillance signal. We aimed to evaluate whether a sentinel approach to active surveillance was more representative of LD risk to human populations, compared to risk-based surveillance.

Methods: We compared enzootic hazard measures (average nymph densities) from sentinel and accessory sites with LD risk (number of human LD cases) across the study area between 2015 and 2019 using local bivariate Moran's I analysis.

Results: Hazard measures from sentinel sites captured spatial risk significantly better than data from accessory sites (χ2=20.473, p<0.001). In addition, sentinel sites successfully tracked the interannual trend in LD case numbers, whereas accessory sites showed no association despite the larger sample size.

Conclusion: Where surveillance aims to document changes in tick-borne disease risk over time and space, we suggest that repeated sampling of carefully selected field sites may be most effective, while risk-based surveillance may be more usefully applied to confirm the presence of emerging disease risk in a specific region of interest or to identify suitable sites for long-term monitoring as LD and other tick-borne diseases continue to emerge.

背景:莱姆病(LD)于本世纪初在魁北克省南部出现,现在许多城市都有流行。自 2014 年以来,魁北克省一直在实施一项协调的主动监测计划,其中包括每年重新采样的数量有限的哨点现场,以及根据 LD 监测信号逐年变化的一组更大的附属现场。我们旨在评估,与基于风险的监测相比,哨点主动监测方法是否更能代表LD对人类的风险:我们使用局部双变量莫兰 I 分析法,比较了 2015 年至 2019 年期间哨点和附属地点的流行病危害测量值(平均若虫密度)与整个研究区域的 LD 风险(人类 LD 病例数):结果:来自哨点的危险度量数据对空间风险的捕捉效果明显优于来自附属点的数据(χ2=20.473,p结论:如果监测的目的是记录蜱传疾病风险在时间和空间上的变化,我们建议对精心挑选的野外地点进行重复采样可能最有效,而基于风险的监测可能更适用于确认特定相关区域是否存在新出现的疾病风险,或在 LD 和其他蜱传疾病不断出现时确定适合进行长期监测的地点。
{"title":"Quality over quantity in active tick surveillance: Sentinel surveillance outperforms risk-based surveillance for tracking tick-borne disease emergence in southern Canada.","authors":"Camille Guillot, Catherine Bouchard, Kayla Buhler, Roxane Pelletier, François Milord, Patrick Leighton","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Lyme disease (LD) emerged in southern Québec at the start of the century, with many municipalities now endemic. A coordinated active surveillance programme has been in place in the province of Québec since 2014, including a limited number of sentinel field sites resampled each year and a larger set of accessory field sites that change yearly according to the LD surveillance signal. We aimed to evaluate whether a sentinel approach to active surveillance was more representative of LD risk to human populations, compared to risk-based surveillance.</p><p><strong>Methods: </strong>We compared enzootic hazard measures (average nymph densities) from sentinel and accessory sites with LD risk (number of human LD cases) across the study area between 2015 and 2019 using local bivariate Moran's I analysis.</p><p><strong>Results: </strong>Hazard measures from sentinel sites captured spatial risk significantly better than data from accessory sites (χ<sup>2</sup>=20.473, <i>p</i><0.001). In addition, sentinel sites successfully tracked the interannual trend in LD case numbers, whereas accessory sites showed no association despite the larger sample size.</p><p><strong>Conclusion: </strong>Where surveillance aims to document changes in tick-borne disease risk over time and space, we suggest that repeated sampling of carefully selected field sites may be most effective, while risk-based surveillance may be more usefully applied to confirm the presence of emerging disease risk in a specific region of interest or to identify suitable sites for long-term monitoring as LD and other tick-borne diseases continue to emerge.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 2-3","pages":"50-58"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Community-based COVID-19 outbreak of the B.1.1.7 (Alpha) variant of concern in Newfoundland, February to March 2021. 2021 年 2 月至 3 月,纽芬兰省社区爆发 COVID-19 B.1.1.7(阿尔法)变种疫情。
Alexandra Nunn, Andrea Morrissey, Ashley Crocker, Kaitlin Patterson, Joanne Stares, Kerri Smith, Laura Gilbert, Krista Wilkinson

Background: From March 2020 to January 2021, Newfoundland and Labrador experienced 408 coronavirus disease 2019 (COVID-19) cases (incidence 78 per 100,000). In February and March 2021, a community outbreak of the B.1.1.7 (Alpha) variant occurred in the Eastern Regional Health Authority. This article describes the epidemiology of this variant of concern outbreak, identifies settings that likely contributed to spread and informs recommendations for public health measures (PHMs).

Methods: Provincial surveillance data were linked with case interview data and a school class roster. Descriptive epidemiological methods were used to characterize the outbreak. Secondary attack rates (SAR) were calculated for households and classrooms.

Results: This outbreak involved 577 laboratory-confirmed and 38 probable cases. Whole genome sequencing determined cases were B.1.1.7. The median age was 31 years and the highest proportion of cases were in the 15 to 19-year age group (29%); 293 (51%) were female and 140 (24%) were asymptomatic upon identification. Early cases were linked to a high school, sports activities, a restaurant and social gatherings. As the outbreak progressed, cases were associated with household transmission, a daycare, healthcare settings and a workplace. The unadjusted SAR estimate among laboratory-confirmed cases was 24.4% for households and 19.3% for classroom exposures. When adjusted for other potential exposures, SAR estimates were 19.9% for households and 11.3% for classrooms.

Conclusion: This outbreak demonstrated how B.1.1.7 spread rapidly through a community with previously low COVID-19 transmission and few preventative PHMs in place. Implementation and compliance with school and community-based PHMs is critical for preventing transmission during outbreaks.

背景:从 2020 年 3 月到 2021 年 1 月,纽芬兰省和拉布拉多半岛发生了 408 例冠状病毒病 2019(COVID-19)病例(发病率为每 10 万人中 78 例)。2021年2月和3月,东部地区卫生局爆发了B.1.1.7(阿尔法)变异株社区疫情。本文描述了这一令人担忧的变异体疫情的流行病学,确定了可能导致传播的环境,并为公共卫生措施(PHMs)的建议提供了信息:方法:将省级监测数据与病例访谈数据和学校班级名册联系起来。采用描述性流行病学方法描述疫情特征。计算了家庭和教室的二次发病率(SAR):此次疫情涉及 577 例实验室确诊病例和 38 例疑似病例。全基因组测序确定病例为 B.1.1.7。病例年龄中位数为 31 岁,15 至 19 岁年龄组的比例最高(29%);293 例(51%)为女性,140 例(24%)在确诊时无症状。早期病例与一所高中、体育活动、一家餐馆和社交聚会有关。随着疫情的发展,病例与家庭传播、日托、医疗机构和工作场所有关。在实验室确诊的病例中,未经调整的 SAR 估计值为:家庭传播 24.4%,教室传播 19.3%。根据其他可能的接触情况进行调整后,家庭的 SAR 估计值为 19.9%,教室的 SAR 估计值为 11.3%:此次疫情表明,B.1.1.7 是如何在一个 COVID-19 传播率低、预防性公共卫生措施少的社区迅速传播的。在疫情爆发期间,实施并遵守基于学校和社区的 PHM 对于预防传播至关重要。
{"title":"Community-based COVID-19 outbreak of the B.1.1.7 (Alpha) variant of concern in Newfoundland, February to March 2021.","authors":"Alexandra Nunn, Andrea Morrissey, Ashley Crocker, Kaitlin Patterson, Joanne Stares, Kerri Smith, Laura Gilbert, Krista Wilkinson","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>From March 2020 to January 2021, Newfoundland and Labrador experienced 408 coronavirus disease 2019 (COVID-19) cases (incidence 78 per 100,000). In February and March 2021, a community outbreak of the B.1.1.7 (Alpha) variant occurred in the Eastern Regional Health Authority. This article describes the epidemiology of this variant of concern outbreak, identifies settings that likely contributed to spread and informs recommendations for public health measures (PHMs).</p><p><strong>Methods: </strong>Provincial surveillance data were linked with case interview data and a school class roster. Descriptive epidemiological methods were used to characterize the outbreak. Secondary attack rates (SAR) were calculated for households and classrooms.</p><p><strong>Results: </strong>This outbreak involved 577 laboratory-confirmed and 38 probable cases. Whole genome sequencing determined cases were B.1.1.7. The median age was 31 years and the highest proportion of cases were in the 15 to 19-year age group (29%); 293 (51%) were female and 140 (24%) were asymptomatic upon identification. Early cases were linked to a high school, sports activities, a restaurant and social gatherings. As the outbreak progressed, cases were associated with household transmission, a daycare, healthcare settings and a workplace. The unadjusted SAR estimate among laboratory-confirmed cases was 24.4% for households and 19.3% for classroom exposures. When adjusted for other potential exposures, SAR estimates were 19.9% for households and 11.3% for classrooms.</p><p><strong>Conclusion: </strong>This outbreak demonstrated how B.1.1.7 spread rapidly through a community with previously low COVID-19 transmission and few preventative PHMs in place. Implementation and compliance with school and community-based PHMs is critical for preventing transmission during outbreaks.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 2-3","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of severe human mpox virus infection with tecovirimat: A case series. 使用替考韦瑞治疗严重的人类 mpox 病毒感染:病例系列。
Koray K Demir, Michaël Desjardins, Claude Fortin, Simon Grandjean-Lapierre, Arpita Chakravarti, François Coutlée, Gerasimos Zaharatos, Jean Morin, Cécile Tremblay, Jean Longtin

Background: Tecovirimat (TCV, TPOXX®) is an orthopox-specific antiviral drug indicated for the treatment of smallpox. There is also a mechanistic basis for its use in mpox infection. However, its approval was based on animal studies, and its efficacy and side-effect profile in human patients with disease is unknown.

Methods: During the 2022 international mpox epidemic, clinicians in Canada accessed TCV from the Public Health Agency of Canada's National Emergency Strategic Stockpile for severe cases of mpox disease. We describe the use of TCV in nine adults with severe mpox virus infection in Montréal, Canada.

Results: Five patients were treated for severe and potentially life-threatening head and neck symptoms, while four were treated for genitourinary or anorectal disease. Two-thirds of patients were also treated for suspected bacterial superinfection. All patients recovered (median time to resolution of severe symptoms: nine days) without relapse or hospital readmission. No patients reported adverse events attributable to TCV and no patients stopped their treatment early.

Conclusion: Our experience suggests that TCV is well tolerated and may accelerate recovery in severe cases. These preliminary, observational data may also be explained by concomitant treatment for superinfection and are limited by the absence of a control group. Controlled, clinical trials should be conducted to clarify the attributable benefit of TCV in severe mpox infection.

背景:特考韦利马特(Tecovirimat,TCV,TPOXX®)是一种天花特异性抗病毒药物,用于治疗天花。它在天花感染中的应用也有一定的机理基础。然而,该药物的批准是基于动物实验,其对人类患者的疗效和副作用尚不清楚:方法:在 2022 年国际水痘疫情期间,加拿大的临床医生从加拿大公共卫生署的国家紧急战略储备中获得了 TCV,用于治疗严重的水痘病例。我们描述了加拿大蒙特利尔市九名严重感染天花病毒的成人使用 TCV 的情况:结果:五名患者因出现严重且可能危及生命的头颈部症状而接受治疗,四名患者因泌尿生殖系统或肛门直肠疾病而接受治疗。三分之二的患者还接受了疑似细菌超级感染的治疗。所有患者均已康复(缓解严重症状的中位时间:9 天),没有复发或再次入院。没有患者报告TCV引起的不良反应,也没有患者提前停止治疗:我们的经验表明,TCV 的耐受性良好,可加速重症患者的康复。这些初步的观察数据也可能是由于同时接受了超级感染治疗所致,并且由于没有对照组而受到限制。应开展对照临床试验,以明确 TCV 对严重水痘感染的益处。
{"title":"Treatment of severe human mpox virus infection with tecovirimat: A case series.","authors":"Koray K Demir, Michaël Desjardins, Claude Fortin, Simon Grandjean-Lapierre, Arpita Chakravarti, François Coutlée, Gerasimos Zaharatos, Jean Morin, Cécile Tremblay, Jean Longtin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Tecovirimat (TCV, TPOXX<sup>®</sup>) is an orthopox-specific antiviral drug indicated for the treatment of smallpox. There is also a mechanistic basis for its use in mpox infection. However, its approval was based on animal studies, and its efficacy and side-effect profile in human patients with disease is unknown.</p><p><strong>Methods: </strong>During the 2022 international mpox epidemic, clinicians in Canada accessed TCV from the Public Health Agency of Canada's National Emergency Strategic Stockpile for severe cases of mpox disease. We describe the use of TCV in nine adults with severe mpox virus infection in Montréal, Canada.</p><p><strong>Results: </strong>Five patients were treated for severe and potentially life-threatening head and neck symptoms, while four were treated for genitourinary or anorectal disease. Two-thirds of patients were also treated for suspected bacterial superinfection. All patients recovered (median time to resolution of severe symptoms: nine days) without relapse or hospital readmission. No patients reported adverse events attributable to TCV and no patients stopped their treatment early.</p><p><strong>Conclusion: </strong>Our experience suggests that TCV is well tolerated and may accelerate recovery in severe cases. These preliminary, observational data may also be explained by concomitant treatment for superinfection and are limited by the absence of a control group. Controlled, clinical trials should be conducted to clarify the attributable benefit of TCV in severe mpox infection.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 2-3","pages":"76-80"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Summary of the NACI Statement on Public Health Level Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-valent and 20-valent Conjugate Vaccines. NACI 关于成人使用肺炎球菌疫苗(包括使用 15 价和 20 价结合疫苗)的公共卫生级建议声明摘要。
Aleksandra Wierzbowski, Robert Pless, Kyla J Hildebrand

Background: Age and certain medical/social conditions are risk factors for invasive pneumococcal disease (IPD). For prevention of IPD, the National Advisory Committee on Immunization (NACI) has recommended the 23-valent polysaccharide pneumococcal vaccine, PNEU-P-23, for adults 65 years of age and older and adults over 18 years of age living with certain underlying conditions. NACI has also recommended 13-valent conjugate pneumococcal vaccine, PNEU-C-13, for adults; however, in publicly funded programs, this recommendation is limited to individuals with risk factors for IPD. Two new conjugate vaccines, PNEU-C-15 and PNEU-C-20, have been authorized by Health Canada for prevention of IPD in adults. This article summarizes NACI public health recommendations for pneumococcal vaccines in adults given these new conjugate vaccines that provide additional serotype coverage over PNEU-C-13.

Methods: Key studies evaluating the immunogenicity and safety of PNEU-C-15 and PNEU-C-20 were reviewed. The Grading of Recommendations, Assessment, Development and Evaluations framework methodology was used to assess the certainty of evidence.

Results: The PNEU-C-15 and PNEU-C-20 vaccines showed comparable immune responses, and safety profiles for all mild, moderate, and severe adverse events, to the currently used vaccines. No data were available on the efficacy or effectiveness of PNEU-C-15 or PNEU-C-20. Economic evidence and feasibility assessments supported the use of the PNEU-C-20 vaccine.

Conclusion: NACI recommends PNEU-C-20 for adults 65 years of age and older, 50-64 years of age and living with factors placing them at higher risk of pneumococcal disease, and 18-49 years of age with immunocompromising conditions, with PNEU-C-15+PNEU-P-23 an alternative.

背景:年龄和某些医疗/社会条件是侵袭性肺炎球菌疾病 (IPD) 的风险因素。为预防 IPD,美国国家免疫咨询委员会 (NACI) 建议 65 岁及以上的成年人和 18 岁以上患有某些基础疾病的成年人接种 23 价肺炎球菌多糖疫苗 PNEU-P-23。NACI 还推荐成人接种 13 价肺炎球菌结合疫苗 PNEU-C-13;不过,在公共资助项目中,这一推荐仅限于有 IPD 危险因素的个人。加拿大卫生部已授权两种新的结合疫苗 PNEU-C-15 和 PNEU-C-20,用于预防成人 IPD。与 PNEU-C-13 相比,这两种新型结合疫苗提供了更多的血清型覆盖范围:方法:回顾了评估 PNEU-C-15 和 PNEU-C-20 免疫原性和安全性的主要研究。结果:PNEU-C-15 和 PNEU-C-20 的免疫原性和安全性的主要研究均得到了评估,并采用了 "建议、评估、开发和评价分级 "框架方法来评估证据的确定性:结果:PNEU-C-15 和 PNEU-C-20 疫苗的免疫反应以及所有轻度、中度和严重不良反应的安全性与目前使用的疫苗相当。目前还没有关于 PNEU-C-15 或 PNEU-C-20 的效力或有效性的数据。经济证据和可行性评估支持使用 PNEU-C-20 疫苗:NACI建议65岁及以上的成年人、50-64岁和生活中存在患肺炎球菌疾病高风险因素的成年人以及18-49岁免疫力低下的成年人接种PNEU-C-20,并将PNEU-C-15+PNEU-P-23作为替代方案。
{"title":"Summary of the NACI Statement on Public Health Level Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-valent and 20-valent Conjugate Vaccines.","authors":"Aleksandra Wierzbowski, Robert Pless, Kyla J Hildebrand","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Age and certain medical/social conditions are risk factors for invasive pneumococcal disease (IPD). For prevention of IPD, the National Advisory Committee on Immunization (NACI) has recommended the 23-valent polysaccharide pneumococcal vaccine, PNEU-P-23, for adults 65 years of age and older and adults over 18 years of age living with certain underlying conditions. NACI has also recommended 13-valent conjugate pneumococcal vaccine, PNEU-C-13, for adults; however, in publicly funded programs, this recommendation is limited to individuals with risk factors for IPD. Two new conjugate vaccines, PNEU-C-15 and PNEU-C-20, have been authorized by Health Canada for prevention of IPD in adults. This article summarizes NACI public health recommendations for pneumococcal vaccines in adults given these new conjugate vaccines that provide additional serotype coverage over PNEU-C-13.</p><p><strong>Methods: </strong>Key studies evaluating the immunogenicity and safety of PNEU-C-15 and PNEU-C-20 were reviewed. The Grading of Recommendations, Assessment, Development and Evaluations framework methodology was used to assess the certainty of evidence.</p><p><strong>Results: </strong>The PNEU-C-15 and PNEU-C-20 vaccines showed comparable immune responses, and safety profiles for all mild, moderate, and severe adverse events, to the currently used vaccines. No data were available on the efficacy or effectiveness of PNEU-C-15 or PNEU-C-20. Economic evidence and feasibility assessments supported the use of the PNEU-C-20 vaccine.</p><p><strong>Conclusion: </strong>NACI recommends PNEU-C-20 for adults 65 years of age and older, 50-64 years of age and living with factors placing them at higher risk of pneumococcal disease, and 18-49 years of age with immunocompromising conditions, with PNEU-C-15+PNEU-P-23 an alternative.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 23","pages":"81-86"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wastewater surveillance for earlier detection of seniors congregate living COVID-19 outbreaks in Peterborough, Ontario. 安大略省彼得伯勒市为及早发现老年人聚居区 COVID-19 爆发而进行的废水监测。
Thomas Piggott, Mohamed Kharbouch, Michael Donaldson, Carolyn Pigeau, Donna Churipuy, Gillian Pacey, Christopher Kyle

The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected seniors living in congregate living settings. The evolving surveillance context has led to novel use of wastewater surveillance to monitor levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in these settings. This study presents a pilot of upstream congregate living wastewater surveillance of SARS-CoV-2 for the detection of COVID-19 outbreaks and the effects of early public health interventions. We monitored localized wastewater SARS-CoV-2 levels from four congregate living settings March 15, 2021 to October 1, 2022 and correlated these levels with suspected and confirmed COVID-19 outbreaks determined by other methods. We identified five wastewater signals that correlated with confirmed outbreaks and three wastewater signals that did not correlate with subsequent outbreaks. In the five confirmed outbreaks, the wastewater signal was detected 2-10 days (median, five days) prior to confirmation of the outbreak by case testing. This pilot demonstrates upstream sampling for SARS-CoV-2 in wastewater may effectively detect outbreaks prior to their detection through symptomatic case testing and could support a balanced approach to outbreak response in congregate living settings, leading to increased wellbeing of these residents.

2019 年冠状病毒病(COVID-19)大流行对居住在集体生活环境中的老年人造成了极大的影响。不断变化的监测环境促使人们采用新颖的废水监测方法来监测这些环境中严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)的水平。本研究介绍了一项对 SARS-CoV-2 进行上游集中式生活废水监测的试点项目,以检测 COVID-19 的爆发情况和早期公共卫生干预措施的效果。我们监测了 2021 年 3 月 15 日至 2022 年 10 月 1 日四个集中居住区的局部废水中的 SARS-CoV-2 水平,并将这些水平与其他方法确定的疑似和确诊 COVID-19 爆发相关联。我们确定了五个与确诊疫情相关的废水信号和三个与后续疫情无关的废水信号。在五次确诊疫情中,废水信号是在病例检测确诊疫情前 2-10 天(中位数为五天)检测到的。这项试验表明,对废水中的 SARS-CoV-2 进行上游采样,可以在通过症状病例检测发现疫情之前有效地检测出疫情,并可支持在集中居住环境中采取平衡的方法应对疫情,从而提高这些居民的健康水平。
{"title":"Wastewater surveillance for earlier detection of seniors congregate living COVID-19 outbreaks in Peterborough, Ontario.","authors":"Thomas Piggott, Mohamed Kharbouch, Michael Donaldson, Carolyn Pigeau, Donna Churipuy, Gillian Pacey, Christopher Kyle","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected seniors living in congregate living settings. The evolving surveillance context has led to novel use of wastewater surveillance to monitor levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in these settings. This study presents a pilot of upstream congregate living wastewater surveillance of SARS-CoV-2 for the detection of COVID-19 outbreaks and the effects of early public health interventions. We monitored localized wastewater SARS-CoV-2 levels from four congregate living settings March 15, 2021 to October 1, 2022 and correlated these levels with suspected and confirmed COVID-19 outbreaks determined by other methods. We identified five wastewater signals that correlated with confirmed outbreaks and three wastewater signals that did not correlate with subsequent outbreaks. In the five confirmed outbreaks, the wastewater signal was detected 2-10 days (median, five days) prior to confirmation of the outbreak by case testing. This pilot demonstrates upstream sampling for SARS-CoV-2 in wastewater may effectively detect outbreaks prior to their detection through symptomatic case testing and could support a balanced approach to outbreak response in congregate living settings, leading to increased wellbeing of these residents.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"49 2-3","pages":"35-43"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cross-sectional investigation of HIV prevalence and risk factors among African, Caribbean and Black people in Ontario: The A/C Study. 对安大略省非洲人、加勒比人和黑人的艾滋病毒感染率和风险因素进行横断面调查:A/C 研究。
Lawrence Mbuagbaw, Winston Husbands, Shamara Baidoobonso, Daeria Lawson, Muna Aden, Josephine Etowa, LaRon Nelson, Wangari Tharao

Background: The human immunodeficiency virus (HIV) epidemic has disproportionately affected African, Caribbean and Black (ACB) communities in Canada. We investigated the prevalence and factors associated with HIV infection among ACB people in Ontario.

Methods: A cross-sectional survey of first- and second-generation ACB people aged 15-64 years in Toronto and Ottawa (Ontario, Canada). We collected sociodemographic information, self-reported HIV status and offered dried blood spot (DBS) testing to determine the prevalence of HIV infection. Factors associated with HIV infection were investigated using regression models.

Results: A total of 1,380 people were interviewed and 834 (60.4%) tested for HIV. The HIV prevalence was 7.5% overall (95% confidence interval [CI] 7.1-8.0) and 6.6% (95% CI 6.1-7.1) in the adult population (15-49 years). Higher age (adjusted odds ratio [aOR] 2.8; 95% CI 2.77-2.82), birth outside of Canada (aOR 4.7; 95% CI 1.50-14.71), French language (aOR 9.83; 95% CI 5.19-18.61), unemployment (aOR 1.85; 95% CI 1.62-2.11), part-time employment (aOR 4.64; 95% CI 4.32-4.99), substance use during sex (aOR 1.66; 95% CI 1.47-1.88) and homosexual (aOR 19.68; 95% CI 7.64-50.71) and bisexual orientation (aOR 2.82; 95% CI 1.19-6.65) were associated with a positive HIV test. Those with a high school (aOR 0.01; 95% CI 0.01-0.02), college (aOR 0.00; 95% CI 0.00-0.01) or university education (aOR 0.00; 95% CI 0.00-0.01), more adequate housing (aOR 0.85; 95% CI 0.82-0.88), a higher social capital score (aOR 0.61; 95% CI 0.49-0.74) and a history of sexually transmitted infections (aOR 0.40; 95% CI 0.18-0.91) were less likely to have a positive HIV test.

Conclusion: Human immunodeficiency virus infection is linked to sociodemographic, socioeconomic, and behavioural factors among ACB people in Ontario.

背景:人类免疫缺陷病毒(HIV)的流行对加拿大的非洲裔、加勒比裔和黑人(ACB)社区造成了极大的影响。我们调查了安大略省非洲、加勒比和黑人群体中艾滋病毒感染的流行情况和相关因素:方法:对多伦多和渥太华(加拿大安大略省)15-64 岁的第一代和第二代非洲、加勒比和黑人进行横断面调查。我们收集了社会人口学信息、自我报告的 HIV 感染状况,并提供了干血斑 (DBS) 检测以确定 HIV 感染率。我们使用回归模型研究了与艾滋病感染相关的因素:共有 1,380 人接受了访谈,其中 834 人(60.4%)接受了艾滋病毒检测。总的 HIV 感染率为 7.5%(95% 置信区间 [CI] 7.1-8.0),成年人(15-49 岁)的感染率为 6.6%(95% 置信区间 [CI] 6.1-7.1)。较高的年龄(调整后的几率比 [aOR] 2.8;95% CI 2.77-2.82)、在加拿大以外出生(aOR 4.7;95% CI 1.50-14.71)、法语(aOR 9.83;95% CI 5.19-18.61)、失业(aOR 1.85;95% CI 1.62-2.11)、兼职(aOR 4.64;95% CI 4.32-4.99)、性生活中使用药物(aOR 1.66;95% CI 1.47-1.88)以及同性恋(aOR 19.68;95% CI 7.64-50.71)和双性恋倾向(aOR 2.82;95% CI 1.19-6.65)与 HIV 检测呈阳性相关。具有高中(aOR 0.01;95% CI 0.01-0.02)、大学(aOR 0.00;95% CI 0.00-0.01)或大学教育程度(aOR 0.00;95% CI 0.00-0.01)、更充足的住房(aOR 0.85;95% CI 0.82-0.88)、更高的社会资本分数(aOR 0.01;95% CI 0.01-0.01)、更高的社会资本分数(aOR 0.01;95% CI 0.01-0.01)和更高的社会资本分数(aOR 0.01;95% CI 0.01-0.01)的人与 HIV 检测呈阳性相关。88)、较高的社会资本得分(aOR 0.61;95% CI 0.49-0.74)和性传播感染史(aOR 0.40;95% CI 0.18-0.91)的人,HIV 检测呈阳性的可能性较低:人类免疫缺陷病毒感染与安大略省 ACB 患者的社会人口、社会经济和行为因素有关。
{"title":"A cross-sectional investigation of HIV prevalence and risk factors among African, Caribbean and Black people in Ontario: The A/C Study.","authors":"Lawrence Mbuagbaw, Winston Husbands, Shamara Baidoobonso, Daeria Lawson, Muna Aden, Josephine Etowa, LaRon Nelson, Wangari Tharao","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The human immunodeficiency virus (HIV) epidemic has disproportionately affected African, Caribbean and Black (ACB) communities in Canada. We investigated the prevalence and factors associated with HIV infection among ACB people in Ontario.</p><p><strong>Methods: </strong>A cross-sectional survey of first- and second-generation ACB people aged 15-64 years in Toronto and Ottawa (Ontario, Canada). We collected sociodemographic information, self-reported HIV status and offered dried blood spot (DBS) testing to determine the prevalence of HIV infection. Factors associated with HIV infection were investigated using regression models.</p><p><strong>Results: </strong>A total of 1,380 people were interviewed and 834 (60.4%) tested for HIV. The HIV prevalence was 7.5% overall (95% confidence interval [CI] 7.1-8.0) and 6.6% (95% CI 6.1-7.1) in the adult population (15-49 years). Higher age (adjusted odds ratio [aOR] 2.8; 95% CI 2.77-2.82), birth outside of Canada (aOR 4.7; 95% CI 1.50-14.71), French language (aOR 9.83; 95% CI 5.19-18.61), unemployment (aOR 1.85; 95% CI 1.62-2.11), part-time employment (aOR 4.64; 95% CI 4.32-4.99), substance use during sex (aOR 1.66; 95% CI 1.47-1.88) and homosexual (aOR 19.68; 95% CI 7.64-50.71) and bisexual orientation (aOR 2.82; 95% CI 1.19-6.65) were associated with a positive HIV test. Those with a high school (aOR 0.01; 95% CI 0.01-0.02), college (aOR 0.00; 95% CI 0.00-0.01) or university education (aOR 0.00; 95% CI 0.00-0.01), more adequate housing (aOR 0.85; 95% CI 0.82-0.88), a higher social capital score (aOR 0.61; 95% CI 0.49-0.74) and a history of sexually transmitted infections (aOR 0.40; 95% CI 0.18-0.91) were less likely to have a positive HIV test.</p><p><strong>Conclusion: </strong>Human immunodeficiency virus infection is linked to sociodemographic, socioeconomic, and behavioural factors among ACB people in Ontario.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"48 10","pages":"429-437"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2021. 加拿大实验室人类病原体和毒素暴露监测,2021 年。
Emily R Thompson, Maryem El Jaouhari, Nadine Eltayeb, Christine Abalos, Megan Striha, Rojiemiahd Edjoc, Collins Ayoo, Samuel Bonti-Ankomah

Background: The Laboratory Incident Notification Canada surveillance system monitors laboratory incidents that are mandated to be reported under the Human Pathogens and Toxins Act and the Human Pathogens and Toxins Regulations. This article describes laboratory exposure incidents that occurred in Canada in 2021 and individuals affected in these incidents.

Methods: We extracted all laboratory incidents occurring in licensed Canadian laboratories in 2021 from the Laboratory Incident Notification Canada system and analyzed them using the software R. We calculated the rate of exposure incidents and performed descriptive statistics by sector, root cause, activity, occurrence type and type of pathogen/toxin. Analysis of the education level, route of exposure, sector, role and laboratory experience of the affected persons was also conducted. We conducted seasonality analysis to compare the median monthly occurrence of exposure incidents between 2016 and 2020 to monthly incidents in 2021.

Results: Forty-three exposure incidents involving 72 individuals were reported to Laboratory Incident Notification Canada in 2021. There were two confirmed laboratory-acquired infections and one suspected infection. The annual incident exposure rate was 4.2 incidents per 100 active licenses. Most exposure incidents involved non-Security Sensitive Biological Agents (n=38; 86.4%) and human risk group 2 (RG2) pathogens (n=27; 61.4%), with bacteria (n=20; 45.5%) and viruses (n=16; 36.4%) as the most implicated agent types. Microbiology was the most common activity associated with these incidents (n=18; 41.9%) and most incidents were reported by the academic sector (n=20; 46.5%). Sharps-related (n=12; 22.2%) incidents were the most common, while human interaction (e.g. workload constraints/pressures/demands, human error) (n=29, 28.2%) was the most common root cause. Most affected individuals were exposed through inhalation (n=38; 52.8%) and worked as technicians or technologists (n=51; 70.8%). Seasonality analyses revealed that the number of exposure incidents reported in 2021 were highest in September and May.

Conclusion: The rate of laboratory incidents was slightly lower in 2021 than in 2020. The most common occurrence type was sharps-related while issues with human interaction was the most cited root cause.

背景:加拿大实验室事故通报监控系统对根据《人类病原体和毒素法》和《人类病原体和毒素条例》必须报告的实验室事故进行监控。本文介绍了 2021 年在加拿大发生的实验室暴露事件以及在这些事件中受到影响的个人:我们从加拿大实验室事故通报系统(Laboratory Incident Notification Canada)中提取了 2021 年加拿大持证实验室发生的所有实验室事故,并使用 R 软件对其进行了分析。我们计算了暴露事故的发生率,并按部门、根本原因、活动、发生类型和病原体/毒素类型进行了描述性统计。我们还对受影响人员的教育水平、接触途径、部门、角色和实验室经验进行了分析。我们进行了季节性分析,将 2016 年至 2020 年每月发生的暴露事件中位数与 2021 年每月发生的事件进行了比较:2021 年,加拿大实验室事故通报部门共收到 43 起暴露事件报告,涉及 72 人。其中有两例确诊的实验室获得性感染和一例疑似感染。年度事故暴露率为每 100 个有效许可证发生 4.2 起事故。大多数暴露事件涉及非安全敏感生物制剂(数量=38;86.4%)和人类风险组 2(RG2)病原体(数量=27;61.4%),其中细菌(数量=20;45.5%)和病毒(数量=16;36.4%)是牵涉最多的制剂类型。微生物学是与这些事件相关的最常见活动(n=18;41.9%),大多数事件由学术部门报告(n=20;46.5%)。与利器相关的事件(12 起,占 22.2%)最为常见,而人为因素(如工作量限制/压力/要求、人为错误)(29 起,占 28.2%)则是最常见的根本原因。大多数受影响的人是通过吸入(38 人,占 52.8%)和作为技术员或技术人员(51 人,占 70.8%)而接触到空气的。季节性分析显示,2021 年报告的接触事故数量在 9 月和 5 月最高:2021年的实验室事故发生率略低于2020年。最常见的事故类型与利器有关,而人际交往问题是最常见的根本原因。
{"title":"Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2021.","authors":"Emily R Thompson, Maryem El Jaouhari, Nadine Eltayeb, Christine Abalos, Megan Striha, Rojiemiahd Edjoc, Collins Ayoo, Samuel Bonti-Ankomah","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The Laboratory Incident Notification Canada surveillance system monitors laboratory incidents that are mandated to be reported under the <i>Human Pathogens and Toxins Act</i> and the <i>Human Pathogens and Toxins Regulations</i>. This article describes laboratory exposure incidents that occurred in Canada in 2021 and individuals affected in these incidents.</p><p><strong>Methods: </strong>We extracted all laboratory incidents occurring in licensed Canadian laboratories in 2021 from the Laboratory Incident Notification Canada system and analyzed them using the software R. We calculated the rate of exposure incidents and performed descriptive statistics by sector, root cause, activity, occurrence type and type of pathogen/toxin. Analysis of the education level, route of exposure, sector, role and laboratory experience of the affected persons was also conducted. We conducted seasonality analysis to compare the median monthly occurrence of exposure incidents between 2016 and 2020 to monthly incidents in 2021.</p><p><strong>Results: </strong>Forty-three exposure incidents involving 72 individuals were reported to Laboratory Incident Notification Canada in 2021. There were two confirmed laboratory-acquired infections and one suspected infection. The annual incident exposure rate was 4.2 incidents per 100 active licenses. Most exposure incidents involved non-Security Sensitive Biological Agents (n=38; 86.4%) and human risk group 2 (RG2) pathogens (n=27; 61.4%), with bacteria (n=20; 45.5%) and viruses (n=16; 36.4%) as the most implicated agent types. Microbiology was the most common activity associated with these incidents (n=18; 41.9%) and most incidents were reported by the academic sector (n=20; 46.5%). Sharps-related (n=12; 22.2%) incidents were the most common, while human interaction (e.g. workload constraints/pressures/demands, human error) (n=29, 28.2%) was the most common root cause. Most affected individuals were exposed through inhalation (n=38; 52.8%) and worked as technicians or technologists (n=51; 70.8%). Seasonality analyses revealed that the number of exposure incidents reported in 2021 were highest in September and May.</p><p><strong>Conclusion: </strong>The rate of laboratory incidents was slightly lower in 2021 than in 2020. The most common occurrence type was sharps-related while issues with human interaction was the most cited root cause.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"48 10","pages":"484-491"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Modelling COVID-19 transmission using IDSIM, an epidemiological-modelling desktop app with multi-level immunization capabilities. 使用 IDSIM(一款具有多级免疫功能的流行病学建模桌面应用程序)模拟 COVID-19 的传播。
Eleodor Nichita, Mary-Anne Pietrusiak, Fangli Xie, Peter Schwanke, Anjali Pandya

Background: : The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented demands on local public health units in Ontario, Canada, one of which was the need for in-house epidemiological modelling capabilities. The objective of this study is to develop a native Windows desktop app for epidemiological modelling, to be used by public health unit epidemiologists to predict COVID-19 transmission in Durham Region.

Methods: : The developed app is an implementation of a multi-stratified compartmental epidemiological model that can accommodate multiple virus variants and levels of vaccination, as well as public health measures such as physical distancing, contact tracing followed by quarantine and testing followed by isolation. It was used to investigate the effects of different factors on COVID-19 transmission, including vaccination coverage, vaccine effectiveness, waning of vaccine-induced immunity and the advent of the Omicron variant. The simulation start date was November 22, 2021.

Results: : For the Delta variant, at least 90% of the population would need to be vaccinated to achieve herd immunity. A Delta-variant-only epidemiological curve would be flattened from the start in the absence of immunity waning and within six months in the presence of immunity waning. The percentage of infections caused by the Omicron variant was forecast to increase from 1% to 97% in the first month of the simulation. Total Omicron infections were forecasted to be reduced, respectively, by 26% or 41% if 3,000 or 5,000 booster doses were administered per day.

Conclusion: : For the Delta variant, both natural and vaccination-induced immunity are necessary to achieve herd immunity, and waning of vaccine-induced immunity lengthens the time necessary to reach herd immunity. In the absence of additional public health measures, a wave driven by the Omicron variant was predicted to pose significant public health challenges with infections predicted to peak in 2-3 months from the start of the simulation, depending on the rate of administration of booster doses.

背景: :2019 年冠状病毒病(COVID-19)大流行对加拿大安大略省的地方公共卫生单位提出了前所未有的要求,其中之一就是需要具备内部流行病学建模能力。本研究的目的是开发一个用于流行病学建模的本地 Windows 桌面应用程序,供公共卫生单位的流行病学家用于预测 COVID-19 在达勒姆地区的传播情况:所开发的应用程序是一个多分层分区流行病学模型的实现,可容纳多种病毒变种和疫苗接种水平,以及物理距离、接触追踪后隔离和检测后隔离等公共卫生措施。该模型用于研究不同因素对 COVID-19 传播的影响,包括疫苗接种覆盖率、疫苗有效性、疫苗引起的免疫力减弱以及 Omicron 变种的出现。模拟开始日期为 2021 年 11 月 22 日:对于德尔塔变体,至少需要 90% 的人口接种疫苗才能实现群体免疫。如果没有免疫力减弱,仅德尔塔变体的流行病学曲线将从一开始就趋于平缓;如果有免疫力减弱,则在 6 个月内趋于平缓。预测在模拟的第一个月,由 Omicron 变体引起的感染比例将从 1%增至 97%。如果每天注射 3,000 或 5,000 强化剂量,预计奥米克隆感染总数将分别减少 26% 或 41%:对于德尔塔变体,自然免疫和疫苗诱导免疫都是实现群体免疫的必要条件,而疫苗诱导免疫的减弱会延长实现群体免疫所需的时间。在没有额外公共卫生措施的情况下,预计由奥米克龙变异体驱动的波将对公共卫生构成重大挑战,根据强化剂的接种率,预计感染高峰将在模拟开始后的 2-3 个月内达到。
{"title":"Modelling COVID-19 transmission using IDSIM, an epidemiological-modelling desktop app with multi-level immunization capabilities.","authors":"Eleodor Nichita, Mary-Anne Pietrusiak, Fangli Xie, Peter Schwanke, Anjali Pandya","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong><b>:</b> The coronavirus disease 2019 (COVID-19) pandemic has placed unprecedented demands on local public health units in Ontario, Canada, one of which was the need for in-house epidemiological modelling capabilities. The objective of this study is to develop a native Windows desktop app for epidemiological modelling, to be used by public health unit epidemiologists to predict COVID-19 transmission in Durham Region.</p><p><strong>Methods: </strong><b>:</b> The developed app is an implementation of a multi-stratified compartmental epidemiological model that can accommodate multiple virus variants and levels of vaccination, as well as public health measures such as physical distancing, contact tracing followed by quarantine and testing followed by isolation. It was used to investigate the effects of different factors on COVID-19 transmission, including vaccination coverage, vaccine effectiveness, waning of vaccine-induced immunity and the advent of the Omicron variant. The simulation start date was November 22, 2021.</p><p><strong>Results: </strong><b>:</b> For the Delta variant, at least 90% of the population would need to be vaccinated to achieve herd immunity. A Delta-variant-only epidemiological curve would be flattened from the start in the absence of immunity waning and within six months in the presence of immunity waning. The percentage of infections caused by the Omicron variant was forecast to increase from 1% to 97% in the first month of the simulation. Total Omicron infections were forecasted to be reduced, respectively, by 26% or 41% if 3,000 or 5,000 booster doses were administered per day.</p><p><strong>Conclusion: </strong><b>:</b> For the Delta variant, both natural and vaccination-induced immunity are necessary to achieve herd immunity, and waning of vaccine-induced immunity lengthens the time necessary to reach herd immunity. In the absence of additional public health measures, a wave driven by the Omicron variant was predicted to pose significant public health challenges with infections predicted to peak in 2-3 months from the start of the simulation, depending on the rate of administration of booster doses.</p>","PeriodicalId":94304,"journal":{"name":"Canada communicable disease report = Releve des maladies transmissibles au Canada","volume":"48 10","pages":"449-464"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10732479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canada communicable disease report = Releve des maladies transmissibles au Canada
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1